CD19 and acute lymphoblastic leukemia: Relapse after CD19-CAR-T therapy can be broadly categorized into two patterns based on the flow cytometry assessment of CD19 expression on B-ALL: CD19-negative relapses (3, 55, 56) and CD19-positive relapses.